Real-time trajectory imaging of alpha particles emitted from actinium-225 and its daughter radionuclides
- PMID: 39833402
- PMCID: PMC11747257
- DOI: 10.1038/s41598-025-87014-7
Real-time trajectory imaging of alpha particles emitted from actinium-225 and its daughter radionuclides
Abstract
In targeted alpha-particle therapy, actinium-225 (Ac-225) has emerged as a radionuclide of potential, driving extensive efforts to develop innovative radiopharmaceuticals. High-resolution imaging of alpha particles is required for precisely detecting alpha-emitting radionuclides in cellular environments and small organs. Here, we report real-time trajectory imaging of alpha particles emitted by Ac-225 and its daughter radionuclides, utilizing an alpha particle trajectory imaging system. This system incorporates a magnification unit, a cooled electron-multiplying charge-coupled device (EM-CCD) camera, and a Ce-doped Gd3Al2Ga3O12 (GAGG) scintillator. Alpha particles were projected onto the GAGG scintillator, producing magnified images that were captured at 100 ms intervals. We successfully tracked particle trajectories with varying lengths and intensities for 4 different alpha particles emitted from Ac-225 and its daughter radionuclides with a spatial resolution of 1.0 μm. Notably, we achieved the imaging of sequentially emitted trajectories from Fr-221 and its decay product At-217, characterized by short decay intervals, along with the extended trajectories of high-energy alpha particles emitted by Po-213. These results demonstrate that high-resolution trajectory imaging, integrated with temporal and energy information, offers profound insights into the real-time behavior of Ac-225 and its daughter radionuclides within living cells or tissue sections, thereby driving advancements in targeted alpha-particle therapy.
Keywords: Actinium-225; Alpha particles; Imaging, energy spectrum; Trajectory.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests.
Figures








Similar articles
-
Development of an ultrahigh resolution real time alpha particle imaging system for observing the trajectories of alpha particles in a scintillator.Sci Rep. 2023 Apr 26;13(1):4955. doi: 10.1038/s41598-023-31748-9. Sci Rep. 2023. PMID: 37100780 Free PMC article.
-
Modeling Cell and Tumor-Metastasis Dosimetry with the Particle and Heavy Ion Transport Code System (PHITS) Software for Targeted Alpha-Particle Radionuclide Therapy.Radiat Res. 2018 Sep;190(3):236-247. doi: 10.1667/RR15081.1. Epub 2018 Jun 26. Radiat Res. 2018. PMID: 29944461 Free PMC article.
-
LaPO4 nanoparticles doped with actinium-225 that partially sequester daughter radionuclides.Bioconjug Chem. 2011 Apr 20;22(4):766-76. doi: 10.1021/bc100574f. Epub 2011 Mar 24. Bioconjug Chem. 2011. PMID: 21434681
-
Actinium-225 targeted alpha particle therapy for prostate cancer.Theranostics. 2024 May 11;14(7):2969-2992. doi: 10.7150/thno.96403. eCollection 2024. Theranostics. 2024. PMID: 38773983 Free PMC article. Review.
-
Actinium-225 in targeted alpha-particle therapeutic applications.Curr Radiopharm. 2011 Oct;4(4):306-20. doi: 10.2174/1874471011104040306. Curr Radiopharm. 2011. PMID: 22202153 Free PMC article. Review.
Cited by
-
Efficacy and Safety of Radioligand Therapy with Actinium-225 DOTATATE in Patients with Advanced, Metastatic or Inoperable Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis.Medicina (Kaunas). 2025 Jul 24;61(8):1341. doi: 10.3390/medicina61081341. Medicina (Kaunas). 2025. PMID: 40870386 Free PMC article.
-
Shake it like an alpha-particle picture.Nat Rev Chem. 2025 Apr;9(4):204. doi: 10.1038/s41570-025-00703-9. Nat Rev Chem. 2025. PMID: 40075214 No abstract available.
References
-
- Kratochwil, C. et al. 225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer. J. Nucl. Med.57, 1941–1944 (2016). - PubMed
-
- Hassan, M. et al. A review of recent advancements in Actinium-225 labeled compounds and biomolecules for therapeutic purposes. Chem. Biol. Drug Des.102(5), 1276–1292 (2023). - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources